Role of Gut Microbiota in Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by inflammation, demyelination, and neurodegeneration. The pathogenesis of MS is complex, involving a combination of genetic, environmental, and immunological factors. Recent research has revealed the potential role of the gut microbiota in the development and progression of MS. The gut microbiota, a diverse and dynamic community of microorganisms, influences immune system function, metabolism, and the integrity of the blood-brain barrier. Dysbiosis, or an imbalance in the gut microbial composition, has been observed in MS patients, with certain bacterial species implicated in the modulation of CNS inflammation and autoimmune responses. Animal models of MS, such as experimental autoimmune encephalomyelitis (EAE), have demonstrated that gut microbiota can significantly affect disease severity and progression. Mechanisms underlying this interaction include the modulation of T-cell responses, regulatory immune cells, and gut-brain signaling pathways. Furthermore, diet and probiotics have been suggested as potential therapeutic strategies to restore microbiota balance and mitigate MS symptoms. However, more research is needed to fully understand the intricate relationship between gut microbiota and MS, and how these findings may be translated into clinical interventions. This review highlights the current understanding of the gut-brain axis in MS and its implications for future therapeutic approaches.